Good science, and new customer behavior mean the time is right for companies to evaluate their portfolios to position themselves for success. Tailwinds are good, private equity interest is high, and the self-care future is bright.
CHPA tracks FDA progress vs. OMUFA goals and activities referenced in legislation. These goals were negotiated between the Agency and Industry prior to the legislation and cover the 5-year period for OMUFA I (October 1, 2020 – September 30, 2025).
The Consumer Healthcare Products Association (CHPA) released the following statement in advance of FDA Advisory Committee meetings considering OTC access to naloxone
The purpose of this cybersecurity and data privacy regulatory scan is to understand the current and forthcoming regulatory landscape related to cybersecurity and consumer data privacy.
Don't miss CHPA President & CEO, Scott Melville's insights on the consumer healthcare industry for the year ahead. Check out this article from Chain Drug Review.
Since mid-November 2022, CHPA's messages about the supply of children's pain-relief and fever-reducing medicines have appeared in over 1,400 news stories.